Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 5/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | EBP | Q15125 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL228872 | 0.90 | LTA4H (0.39) | LTA4HESR1ESR2HRH3MAOB | |
| SCHEMBL225172 | 0.81 | GRIN1 (0.34) | ESR1ESR2HRH3MAOBSIGMAR1 | |
| SCHEMBL228676 | 0.81 | ACHE (0.34) | HRH3SIGMAR1 | |
| SCHEMBL226855 | 0.79 | LTA4H (0.45) | LTA4HESR1ESR2HRH3MAOB | |
| SCHEMBL227595 | 0.78 | LTA4H (0.39) | LTA4HESR1ESR2HRH3 | |
| SCHEMBL226486 | 0.77 | LTA4H (0.45) | LTA4HESR1ESR2HRH3MAOB | |
| SCHEMBL227585 | 0.76 | LTA4H (0.39) | LTA4HESR1ESR2HRH3 | |
| SCHEMBL227766 | 0.75 | LTA4H (0.49) | LTA4HESR1ESR2HRH3MAOB | |
| SCHEMBL229972 | 0.75 | LTA4H (0.49) | LTA4HESR1ESR2HRH3MAOB | |
| SCHEMBL226141 | 0.74 | MMP1 (0.39) | LTA4HESR1ESR2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI CO., LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | BRCA1, BCR, RCC1 | LTA4H 3104/4885ESR1 34/4885ESR2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.